Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Non-Small-Cell Lung Carcinoma NSCLC
Interventions: MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 35
States / cities: Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more

Conditions: Non Small Cell Lung Carcinoma NSCLC
Interventions: Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 953 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 15
States / cities: Anaheim, California • San Diego, California • Santa Rosa, California + 12 more

Conditions: Cardiovascular
Interventions: AZD1705, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Glendale, California • Jacksonville, Florida • Winter Park, Florida + 2 more

Conditions: Urinary Bladder Neoplasms
Interventions: Durvalumab, Olaparib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Goodyear, Arizona • Fort Myers, Florida + 9 more

Conditions: Ovarian Cancer
Interventions: olaparib, paclitaxel, carboplatin, Drug: carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 125 Years · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 8
States / cities: Stanford, California • West Hollywood, California • Orlando, Florida + 4 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 8
States / cities: Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more

Conditions: Non Small Cell Lung Cancer (Stage III)
Interventions: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: Duarte, California • Atlanta, Georgia • Florham Park, New Jersey + 2 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Elecoglipron, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 14 more

Conditions: Healthy Participants
Interventions: AZD4954, Laroprovstat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Stage II-IIIB Non-small Cell Lung Carcinoma
Interventions: Osimertinib 80 mg/40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Santa Rosa, California • Las Vegas, Nevada • White Plains, New York

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Commack, New York • Harrison, New York • New York, New York + 5 more

Conditions: Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
Interventions: Anifrolumab; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Anifrolumab for Hidradenitis Suppurativa

About this AstraZeneca sponsor directory page